ZHZubair Hussain

Zubair Hussain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zubair Hussain has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Divergent global trajectories of oesophageal squamous-cell carcinoma mortality, 1990 to 2040: a six-region modelling study

    by Muhammad Asad Nawaz, Zubair Hussain, Ling Shuying, Ling Zhu, Adnan Naz, Muhammad Usman, Agila Mohammed, Li Han, Yu Rian

    Background Oesophageal squamous-cell carcinoma (ESCC) is a leading cause of cancer death in low and middle SDI regions. We characterised the heterogeneity of mortality trajectories across six world regions using contemporary methods. Methods We analysed Global Burden of Disease Study 2021 age-standardised mortality rates (1990-2021) using dynamic-programming changepoint detection, Bayesian state-space forecasting to 2040, Das Gupta demographic decomposition, and stochastic frontier analysis. Results Global ASMR declined from 9.01 to 6.12 per 100,000 (AAPC -1.24% per year, 95% CI -1.49 to -1.01), with a synchronised inflection at 2005. Central Asia showed the steepest decline (AAPC -3.30%), whereas Western Sub-Saharan Africa was the only region with a rising trajectory (AAPC +1.56%). Bayesian projections indicate a further 41% rise in Western Sub-Saharan Africa by 2040. East Asia operated at 40% of the achievable burden minimum. Conclusions ESCC mortality trajectories are diverging globally. Region-specific interventions including tobacco control, hot-beverage cooling, mycotoxin mitigation, and AI-assisted endoscopy are needed to reduce preventable mortality.

  • Open Access

    Differential Gene Expression Analysis of TCGA Cancer Transcriptomes with DESeq2 and Pathway Enrichment v1

    by Hussain Zubair

    This protocol provides a validated workflow for differential gene expression analysis of TCGA RNA-seq data. It covers data retrieval via TCGAbiolinks, normalization decisions, differential expression with DESeq2 and apeglm shrinkage, gene ID conversion, and three pathway analysis approaches: ORA, GSEA, and sample-level scoring with GSVA. Each step includes benchmark values validated against TCGA-LUAD (n=540 tumor, 59 normal). The protocol addresses common pitfalls including inappropriate use of TPM for statistical testing and pre-filtering of gene lists before GSEA.

  • WITHDRAWN: Design and Evaluation of Floating Micro-Carriers for Effective Delivery of a Hydrophobic Drug

    by Wu Yong, Zubair Hussain, Lui Hongcai, Zhu Ling, Muhammad Asad Nawaz, Adnan Falak Naz

    The article has been withdrawn at the request of the authors of the journal "Current Drug Delivery", Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused. The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php Bentham Science Disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.

  • Open Access

    Triple combination of SPR741, clarithromycin, and erythromycin againstAcinetobacter baumanniiand its tolerant phenotype

    by Zehao Li, Pengfei She, Yaqian Liu, Lanlan Xu, Yimin Li, Shasha Liu, Zubair Hussain, Linhui Li, Yifan Yang, Yong Wu

    Extensively drug-resistant (XDR) Acinetobacter baumannii poses a severe threat to public health due to its ability to form biofilms and persister cells, which contributes to critical drug resistance and refractory device-associated infections. A novel strategy to alleviate such an emergency is to identify promising compounds that restore the antimicrobial susceptibility of existing antibiotics against refractory infections. Here, we found a significant synergy among three combinations of SPR741, clarithromycin and erythromycin with a potent antimicrobial activity against XDR A. baumannii (SPR741/CLA/E at 8/10/10 μg ml–1 for XDR AB1069 and at 10/16/10 μg ml–1 for XDR AB1208, respectively). Moreover, the triple combination therapy exhibits a significant antipersister and antibiofilm effect against XDR strains. Mechanistic studies demonstrate that SPR741 may promote intracellular accumulation of macrolides by permeabilizing the outer membrane as well as disrupting membrane potential and further enhance the quorum sensing inhibition activity of the macrolides against XDR A. baumannii and its biofilms. In addition, the triple combination of SPR741 with clarithromycin and erythromycin was not easy to induce resistance in A. baumannii and had effective antimicrobial activity with low toxicity in vivo. Collectively, these results reveal the potential of SPR741 in combination with clarithromycin and erythromycin as a clinical therapy for refractory infections caused by XDR A. baumannii.


  • Study on antibacterial effect of halicin (SU3327) against Enterococcus faecalis and Enterococcus faecium

    by Zubair Hussain, She Pengfei, Li Yimin, Liu Shasha, Li Zehao, Yang Yifan, Li Linhui, Zhou Linying, Wu Yong

    Enterococci are important pathogens of nosocomial infections and are increasingly difficult to treat due to their intrinsic and acquired resistance to a range of antibiotics. Therefore, there is an urgent need to develop novel antibacterial agents, while drug repurposing is a promising approach to address this issue. Our study aimed to determine the antimicrobial efficacy of halicin against enterococci and found that the minimum inhibitory concentrations (MIC) of halicin against different strains of Enterococcus faecalis and Enterococcus faecium ranged from 4 to 8 μg/ml. In addition, the synergistic antibacterial effect between halicin and doxycycline (DOX) against Enterococcus was observed through the checkerboard method, and it was observed that halicin and DOX could significantly synergistically inhibit biofilm formation and eradicate preformed biofilms at sub-MICs. Moreover, the electron microscope results revealed that halicin could also disrupt the bacterial cell membrane at high concentrations. Furthermore, it is also confirmed that the combination of halicin and DOX has no significant cytotoxic effect on erythrocytes and other human-derived cells. In addition, the mouse subcutaneous model and H&E staining showed that the combination of halicin and DOX could effectively reduce the bacterial load and inflammatory infiltration without obvious side effects. In nutshell, these results demonstrate the potential of halicin in combination with DOX as a novel therapy against infections by Enterococcus.


  • Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax

    by Hongcai Liu, Zubair Hussain, Qingqing Xie, Xueying Yan, Chenxing Zeng, Gan Zhou, Shan Cao